

## IMSPATENTS (IMS LifeCycle Patent Focus)

<b>Subject Coverage</b>	<ul style="list-style-type: none"> <li>• Commercially significant drugs</li> <li>• Patent family information</li> </ul>
<b>File Type</b>	Substance, Patent
<b>Features</b>	<p>Thesaurus</p> <p><a href="#">Alerts (SDIs)</a> Monthly</p> <p><a href="#">CAS Registry Numbers®</a> <input checked="" type="checkbox"/> Page Images <input type="checkbox"/> STN AnaVist <input type="checkbox"/></p> <p><a href="#">Keep &amp; Share</a> <input checked="" type="checkbox"/> <a href="#">SLART</a> <input checked="" type="checkbox"/> STN Easy <input type="checkbox"/></p> <p>Learning Database <input type="checkbox"/> Structures <input type="checkbox"/> STN Viewer <input type="checkbox"/></p>
<b>Record Content</b>	<ul style="list-style-type: none"> <li>• Full text reports</li> <li>• CAS Registry Number and Chemical Name</li> <li>• Company name</li> <li>• Source Information</li> </ul>
<b>File Size</b>	More than 207,620 records (12/11)
<b>Coverage</b>	1995-present
<b>Updates</b>	Monthly
<b>Language</b>	English
<b>Database Producer</b>	IMS HEALTH (IMSworld Publications Ltd) Customer Services Dept. Global Services 7 Harewood Ave. London NW1 6JB United Kingdom Phone: (+44) 020 7393 5888 Fax: (+44) 020 7393 5346 E-mail: <a href="mailto:service@imshealth.com">service@imshealth.com</a> Web: <a href="http://www.imshealth.com/global">http://www.imshealth.com/global</a>
<b>Sources</b>	Conferences, interviews with company representatives, press releases, and phone/fax contacts with companies.
<b>User Aids</b>	Online Helps (HELP DIRECTORY lists all help messages available) STNGUIDE

**IMSPATENTS**

---

**Clusters**

- CASRNS
- COMPANIES
- CORPSOURCE
- FORMULATIONS
- HPATENTS
- IMSBASES
- PATENTS
- PHARMACOLOGY

[STN Database Cluster](#) information (PDF).

---

**Pricing**

See the [STN Price List](#) or enter HELP COST at an arrow prompt (=>).

---

## Search and Display Field Codes

Fields that allow left truncation are indicated by an asterisk (\*).

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index * (contains single words from the chemical name (CN), trade name (TN), corporate name (CO), patent assignee (PA), classification code (CC), supplementary term (ST), text (TX), and abstract (AB) fields, as well as CAS Registry Numbers)	None (or /BI)	S MALARIA S BACTERIAL INFECTION S CYPROTERONE S 85721-33-1	AB, CC, CN, CO, PA, RN, ST, TN, TX
Abstract *	/AB	S (WATER(1W)OIL/AB S HIGH TEMP?/AB S (HIV(S)TREAT?)/AB	AB
Accession Number	/AN	S 95:45/AN S 2005:106/AN	AN
Application Date (1)	/AD	S 20001029/AD	PI
Application Year (1)	/AY	S 1983-1985/AY	PI
Chemical Name (includes generic, lab, and trade names)	/CN	S CIPROFLOXACIN/CN S BAY 0 9867/CN	CN, RN, TN
Chemical Name Segment *	/CNS	S ?TERONE?/CNS	CN, RN, TN
Classification Code (3) (code and text)	/CC	S J1A/CC S HORMONAL CONTRACEPTIVES/CC	CC
Company Name (Corporate Name, Corporate Source) (4) (contains corporate name, patent assignee, and country name)	/CO (or /CS)	S BAYER/CO S ABBOTT HAKKO/CO S (MERCK (L) USA)/CO	CO, PA
Controlled Term	/CT	S ECZEMA/CT	CT
Crossover Key	/CK	S 3536?/CK	CK
Data Entry Date (1)	/DED	S DED>=20030828 S 28 JAN 2001/DED	SO
Designated States (ISO code and text)	/DS	S DE/DS S GERMANY?/DS	DS
Document Number	/DN	S 239099/DN	DN
Entry Date (1)	/ED	S 20010215/ED	ED
Expiration Date (1)	/XPD	S XPD>=DEC 30, 1996	PI
Expiration Year (1)	/XPY	S XPY>=2010	PI
Family Number	/FN	S 8221/FN	FN
Field Availability	/FA	S AB/FA	FA
Highest Development Phase	/HDP	S MARKETED/HDP	HDP
Journal Title (5)	/JT	S PATENTS INTERNATIONAL/JT	JT, SO
Other Source	/OS	S 1993:576/OS	OS
Patent Assignee (contains assignee and country) (4)	/PA	S BAYER/PA S LEDERLE BIOLOGICALS/PA S (MERCK (L) CANADA)/PA	PA
Patent Assignee Address	/PAA	S GERMANY?/PAA	PA
Patent Country (ISO code and text)	/PC	S EP/PC S GERMANY?/PC	PI
Patent Number (2)	/PN	S EP49355/PN	PI
Patent Number/Kind Code	/PNK	S US20090010877/PNK	PNK
Patent Publication Date (1)	/PD	S 19970602/PD	PI
Patent Publication Year (1)	/PY	S PY>=2000	PI

**IMSPATENTS****Search and Display Field Codes (cont'd)**

Search Field Name	Search Code	Search Examples	Display Codes
Priority Country (ISO code and text)	/PRC	S DE/PRC	PRAI
Priority Date (1)	/PRD	S GERMANY?/PRC S 20000903/PRD S PRD>=DEC 31 2003	PRAI
Priority Number (2)	/PRN	S DE80-3033157/PRN	PRAI
Priority Year (1)	/PRY	S 1999/PRY	PRAI
Reference	/RE	S PINN/RE	Not displayable
Source (contains title, date of publication, and year of publication) (5)	/SO	S (PATENTS INTERNATIONAL AND JAN 2001)/SO	SO
Stage	/STG	S 80/STG	STG
Supplementary Term	/ST	S PRODUCT/ST S METHOD OF USE/ST	ST
Text *	/TX	S HORMONE/TX	TX
Trade Name	/TN	S CIPROBAY/TN	CN, TN
Update Date (1)	/UP	S L1 AND UP>20010100	UP

(1) Numeric search field that may be searched using numeric operators or ranges.

(2) Either STN format or Derwent format may be used.

(3) Search with implied (S) proximity is available in this field.

(4) Search with implied (S) proximity is available in this field within the names. Use (L) proximity between the name and the country.

(5) The source for all records is Patents International.

**Super Search Fields**

Enter a super search code to execute a search in one or more fields that may contain the desired information. Super search fields facilitate crossfile and multifile searching. EXPAND may not be used with super search fields. Use EXPAND with the individual field codes instead.

Search Field Name	Search Code	Fields Searched	Search Examples	Display Codes
Application Number Group (1)	/APPS	/PRN	S DE81-3142854/APPS S 81DE-3142854/APPS	PRAI
Patent Countries (ISO code and text)	/PCS	/PC, /DS	S DE/PCS S GERMANY?/PCS	DS, PI
Patent Number Group (1)	/PATS	/PN	S EP49355/PATS S EP--49355/PATS S EP0049355/PATS	PI

(1) Either STN format or Derwent format may be used.

## DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 CN AB. Fields are displayed or printed in the order requested.

Hit-term highlighting is available in all fields except FA. In the display of PI and PRAI, highlighting is shown by an arrow on the right side pointing to the line that includes the hit terms. Highlighting must be ON during SEARCH to use the HIT, KWIC, and OCC display formats.

Format	Content	Examples
AB	Abstract	D AN AB
AN (2)	Accession Number	D L4 1-4 AN
CC (2)	Classification Code	D CN CC
CK	Crossover Key	D CK
CN	Chemical Name (includes Generic Name, Lab Code, Trade Name, RN)	D CN
CO (CS)	Company Name (Corporate Name, Corporate Source) (includes PA)	D CO
CT	Controlled Term (includes clinical application data)	D CT
DN	Document Number	D DN
DS	Designated States	D PI DS
ED	Entry Date	D ED
FA (2,3)	Field Availability	D L3 1,10 FA
FN	Family Number	D FN
HDP	Highest Development Phase (Phase I-III, Marketed, etc.)	D HDP
JT (2,3)	Journal Title	D IDE JT
OS	Other Source	D OS
PA	Patent Assignee	D PI PA 1-10
PCS	Patent Countries	D PCS
PI (PN, PATS) (1)	Patent Information	D PI
PNK (7)	Patent Number/Kind Code	D PNK
PRAI (PRN) (1)	Priority Information	D PRAI
RN	CAS Registry Number	D RN
SO (2)	Source	D SO
ST	Supplementary Term	D CC ST
STF (3)	Flat Structure (no stereo indicated)	D CN STF
STG	Stage (numeric values corresponding to /HDP)	D STG
STR (4)	Structure Diagram (includes stereo bonds and R/S/E/Z labels when available)	D CN RN STR
STS (3,4)	Stereo Structure ((includes stereo bonds when available))	D CN STS
TN (3)	Trade Name	D TN
TX	Text (Expiry Comments and Country Comments)	D TX
UP	Update Date	D UP
ALL (1,4)	AN, SO, CN, RN, STR, RN Derivatives, CC, PA, CO, ST, PI, DS, PRAI, TX, AB	D L1 1- ALL
APPS (1)	PRAI	D APPS
CYD (1,5)	AN, SO, CN, CC, ST, PI, DS, TX	D CYD
IALL (1,4)	ALL, indented with text labels	D IALL
ICYD (1,5)	CYD, indented with text labels	D ICYD
IDE (4)	AN, SO, CN, RN, STR, RN Derivatives, CC	D IDE
IIDE (4)	IDE, indented with text labels (IIDE is the default)	D
ISTD (1,4)	STD, indented with text labels	D ISTD 1-3
PITAB	Table containing publication numbers, publication date, filing date, expiry date, and country for patent family members	D PITAB
SCAN (2,6)	AN, CC	D SCAN
STD (1,4)	AN, SO, CN, RN, STR, RN Derivatives, CC, PA, CO, ST, PI, DS, PRAI	D STD
TRIAL (TRI, SAM) (2)	AN, CC	D TRIAL
CCTAB (5)	Table containing CC, CN, PA for a single answer or several records in a single table	TOTAL D CCTAB 1-5
COTAB (1,5)	Table containing PA, CN, PN for a single answer or several records in a single table	D COTAB L1 1
CYTAB (1)	Table containing PC, PN, DS, AP, Expiry Date, Expiry Comments, Country Comments for a single answer or several records in a single table	D CYTAB 1-10

## DISPLAY and PRINT Formats (cont'd)

Format	Content	Examples
IDETAB (5)	Table containing RN, CN, CC for a single answer or several records in a single table	D IDETAB 1-4
HIT KWIC OCC (2)	Fields containing hit terms Hit terms plus 20 words on either side (KeyWord-In-Context) Number of occurrences of hit terms and fields in which they occur	D HIT D KWIC NOH D OCC

- (1) By default, patent, application, and priority numbers are displayed in STN format. To display them in Derwent format, enter SET PATENT DERWENT at an arrow prompt. To reset display to STN format, enter SET PATENT STN.
- (2) No online display fee for this format.
- (3) Custom display only.
- (4) Stereo structure diagrams are only available on graphics terminals and offline prints.
- (5) CN in these formats includes only the first generic name.
- (6) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.
- (7) PNK format does not display a kind code.

## SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Abstract	AB	Y (2)	N
Accession Number	AN	Y	N
Application Number and Priority Number	APPS	Y (3,4)	N
Application Year	AY	Y	N
CAS Registry Number	RN	Y (2)	N
CAS Registry Number and Chemical Name	CHEM	Y (2)	N
Chemical Name	CN	Y (5) (default)	N
	NAME	Y (6)	N
Classification Code	CC	Y	Y
Company Name (Corporate Name, Corporate Source) and Patent Assignee	CO	Y (7)	Y
	CS	Y	Y
Controlled Term	CT	Y	N
Crossover Key	CK	Y	N
Data Entry Date	DED	Y	Y
Designated States	DS	Y	N
Document Number	DN	Y	Y
Entry Date	ED	Y	Y
Expiration Date	XPD	Y (3)	Y
Expiration Year	XPY	Y (3)	Y
Family Number	FN	Y	N
Highest Development Phase	HDP	Y	Y
Journal Title	JT	Y	Y
Occurrence Count of Hit Terms	OCC	N	Y
Other Source	OS	Y	N
Patent Assignee	PA	Y	Y
Patent Assignee Address	PAA	Y	N
Patent Countries	PCS	Y (8)	N
Patent Country	PC	Y (3)	Y
Patent Information	PI	N	Y

**SELECT, ANALYZE, and SORT Fields (cont'd)**

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Patent Number	PN	Y (3,4)	Y
Patent Number Group	PATS	Y (3,4,9)	N
Patent Number/Kind Code	PNK	Y	N
Priority Country	PRC	Y (3)	Y
Priority Date	PRD	Y (3)	Y
Priority Information	PRAI	Y (3,4,10)	Y
Priority Number	PRN	Y (3,4)	Y
Priority Year	PRY	Y (3)	Y
Publication Date	PD	Y (3)	Y
Publication Year	PY	Y (3)	Y
Source	SO	Y	N
Stage	STG	Y	Y
Supplementary Term	ST	Y	N
Text	TX	Y (2)	N
Trade Name	TN	Y	Y
Update Date	UP	Y	Y

- (1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT CN.
- (2) Appends /BI to the terms created by SELECT.
- (3) SELECT HIT and ANALYZE HIT are not valid with this field.
- (4) Enter SET PATENT DERWENT at an arrow prompt (=>) to SELECT or ANALYZE patent, application, and priority numbers in Derwent format.
- (5) Selects or analyzes the generic, lab, and trade names in the RN field with /CN appended to the terms created by SELECT.
- (6) Selects or analyzes the generic, lab, and trade names with /BI appended to the terms created by SELECT.
- (7) Appends /CS to the terms created by SELECT.
- (8) Selects or analyzes the PC and DS with /PCS appended to the terms created by SELECT.
- (9) Selects or analyzes the PN with /PATS appended to the terms created by SELECT.
- (10) Selects or analyzes the PRN with /PRN appended to the terms created by SELECT.

## IMSPATENTS

## Sample Records

## DISPLAY IIIDE (Default)

ACCESSION NUMBER: 2011:4309 IMSPATENTS  
 DOCUMENT NUMBER: 329420 (Country Drug Key)  
 FAMILY NUMBER: 8226 (Drug Family Key)  
 SOURCE: Patents International, (15 Mar 2011)  
 OTHER SOURCE: IMSRESEARCH 1996:1043  
 ENTRY DATE: Entered STN: 29 Mar 2011  
 Last Updated on STN: 30 Aug 2011  
 GENERIC NAME: exendin 4 (heloderma suspectum); exenatide;  
 exenatide  
 REFERENCE: pINN; USAN  
 LABORATORY CODE: AC 2993; LY 2148568  
 TRADE NAME: BYETTA  
 CHEMICAL NAME: L-histidylglycyl-L-a-glutamylglycyl-L-threonyl-L-  
 phenylalanyl-L-threonyl-L-seryl-L-a-aspartyl-L-leucyl-  
 L-seryl-L-lysyl-L-glutaminy-L-methionyl-L-a-glutamyl-  
 L-a-glutamyl-L-a-glutamyl-L-alanyl-L-valyl-L-arginyl-L-  
 leucyl-L-phenylalanyl-L-isoleucyl-L-a-glutamyl-L-  
 tryptophyl-L-leucyl-L-lysyl-L-asparaginyglycylglycyl-  
 L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-  
 prolyl-L-prolyl-L-serinamide  
 CAS REGISTRY NUMBER: 141758-74-9  
 STRUCTURE:  
 STRUCTURE DIAGRAM IS NOT AVAILABLE  
 DERIVATIVE(S): 141758-74-9 exenatide  
 CLASSIFICATION: N4A Anti-parkinson Drugs; N6A9 Antidepressants; N7X  
 All Other CNS Drugs; A10S GLP-1 Agonist Antidiabetics  
 INDICATION: depression; diabetes; Parkinson disease; post  
 traumatic stress disorder  
 PHARMACOLOGY: peptide; GLP-1 agonist  
 HIGHEST DEV. PHASE: Marketed (80)

## DISPLAY IALL (Same record as above but in different format)

ACCESSION NUMBER: 2011:4309 IMSPATENTS  
 DOCUMENT NUMBER: 329420 (Country Drug Key)  
 FAMILY NUMBER: 8226  
 OTHER SOURCE: IMSRESEARCH 1996:1043  
 SOURCE: Patents International, (15 Mar 2011)  
 ENTRY DATE: Entered STN: 29 Mar 2011  
 Last Updated on STN: 30 Aug 2011  
 GENERIC NAME: exendin 4 (heloderma suspectum); exenatide;  
 exenatide  
 REFERENCE: pINN; USAN  
 LABORATORY CODE: AC 2993; LY 2148568  
 TRADE NAME: BYETTA  
 CHEMICAL NAME: L-histidylglycyl-L-a-glutamylglycyl-L-threonyl-L-  
 phenylalanyl-L-threonyl-L-seryl-L-a-aspartyl-L-leucyl-  
 L-seryl-L-lysyl-L-glutaminy-L-methionyl-L-a-glutamyl-  
 L-a-glutamyl-L-a-glutamyl-L-alanyl-L-valyl-L-arginyl-L-  
 leucyl-L-phenylalanyl-L-isoleucyl-L-a-glutamyl-L-  
 tryptophyl-L-leucyl-L-lysyl-L-asparaginyglycylglycyl-  
 L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-  
 prolyl-L-prolyl-L-serinamide  
 CAS REGISTRY NUMBER: 141758-74-9  
 STRUCTURE:  
 STRUCTURE DIAGRAM IS NOT AVAILABLE  
 DERIVATIVE(S): 141758-74-9 exenatide  
 CLASSIFICATION: N4A Anti-parkinson Drugs; N6A9 Antidepressants; N7X  
 All Other CNS Drugs; A10S GLP-1 Agonist Antidiabetics

INDICATION: depression; diabetes; Parkinson disease; post traumatic stress disorder  
 PHARMACOLOGY: peptide; GLP-1 agonist  
 HIGHEST DEV. PHASE: Marketed (80)  
 PATENT ASSIGNEE: Amylin (USA)  
 CORPORATION: Amylin (USA)  
 SUPPLEMENTARY TERM: Method of use

## PATENT INFORMATION:

Publication Number	Patent Type	Publication Date	Filing Date	Expiration Date
HK 1046105	Application	20021227	20000114	

PRIORITY INFORMATION: US 1999-116380P 19990114  
 US 1999-132017P 19990430  
 US 2000-175365P 20000110  
 US 2002-157224 20020528

TEXT: Expiry Comments: Application (2002); Withdrawn (2010)

Country Comments: Hong Kong application HK1046105 is based on Chinese patent CN100425284 and claims a method of lowering plasma glucagon in a subject, comprising administering a therapeutically effective glucagon lowering amount of a compound selected from an exendin, an exendin agonist, a modified exendin and a modified exendin agonist.

Exenatide (exendin-4) is claimed specifically.

Hong Kong application HK1046105 was withdrawn in January 2010.

## ABSTRACT:

The patent family listed here contains four Patent Cooperation Treaty (PCT) applications:

- WO0041546, quoting the US19990116380P and US20000175365P priorities, claims a formulation comprising an exendin or an exendin agonist peptide, a buffer and an iso-osmolality modifier, the formulation having a pH of between 3.0 and 7.0. There are specific claims for a parenteral liquid formulation and for a solid or dry powder formulation;
- WO0041548, quoting the US19990116380P, US19990132017P and US20000175365P priorities, claims a method of lowering plasma glucagon in a subject, comprising administering a therapeutically effective glucagon-lowering amount of a compound selected from an exendin, an exendin agonist, a modified exendin and a modified exendin agonist. Exenatide (exendin-4) is claimed specifically;
- WO0151078, quoting the US20000175365P priority, claims a method for modulating triglyceride levels in a subject comprising administering a therapeutically effective amount of an exendin or an exendin agonist. Exenatide (exendin-4) is claimed specifically. The exendin or exendin agonist may be administered daily by injection, preferably by subcutaneous injection; and
- WO03099314, quoting the US20020157224 priority, claims a composition comprising an exendin or an exendin agonist peptide in an extended-release formulation, the formulation being capable of releasing the peptide over a predetermined release period in an amount such that, when the composition is administered to a human, an average sustained plasma level is achieved for the predetermined release period. Exenatide (exendin-4) is claimed specifically.

This family relates to the BYETTA formulations of synthetic exenatide.

## IMSPATENTS

## DISPLAY CYTAB

ANS	Country	Publication Number(s)	Expiry Date	Expiry Comments	NOTE
1	Hong Kong	HK 1046105		Application (2002); Withdrawn (2010)	(1), (2), (3)
2	United States	US 20110034377	20160808	Application (2011)	(4)
3	Hong Kong	HK 1023948	20170808	Application (2000); Withdrawn (2009)	(5), (6)
4	United States	US 20050043238 US 7741269	20180107	Granted (2010)	(7), (8), (9), (10), (11)
5	United States	US 20090215694	20200114	Application (2009)	(12), (13)
6	Singapore	SG 81736 SG 81736	20200114	Granted (2003)	(14), (2)
7	Singapore	SG 81737 SG 81737	20200114	Granted (2004)	(15)
8	Sweden	EP 1658856 EP 1658856	20200114	Granted (2010); Lapsed (2010)	(16), (2), (17)
9	Portugal	EP 1658856 EP 1658856	20200114	Granted (2010); Lapsed (2010)	(16), (2), (18)
10	Netherlands	EP 1658856 EP 1658856	20200114	Granted (2010); Lapsed (2010)	(16), (2), (19)

## Country Comments:

- (1) Country Comments: Hong Kong application HK1046105 is based on Chinese patent CN100425284 and claims a method of lowering plasma glucagon in a subject, comprising administering a therapeutically effective glucagon lowering amount of a compound selected from an exendin, an exendin agonist, a modified exendin and a modified exendin agonist.
- (2) Exenatide (exendin-4) is claimed specifically.
- (3) Hong Kong application HK1046105 was withdrawn in January 2010.
- (4) Country Comments: US application US2011034377 claims a method for treating an eating disorder in a human by administering exenatide.
- (5) Country Comments: Hong Kong application HK1023948 is based on EP0966297 B and claims exenatide specifically as product for use in the treatment of a disease which may be benefited by a decrease in gastrointestinal motility.
- (6) Hong Kong application HK1023948 was withdrawn in August 2009.
- (7) Country Comments: US patent US7741269 claims a method for reducing body weight by administering exenatide.
- (8) The term of US patent US7741269 has been extended/adjusted by 696 days under 35 U.S.C.154(b), however, this patent has also been disclaimed from the expiry date of US patent US6956026. Therefore, the estimated expiry date of US patent US7741269 is 7 January 2018.
- (9) US patent US7741269 is quoted by the FDA Orange Book as relating to the BYETTA subcutaneous injectable formulations of synthetic exenatide for the use of exenatide may result in reduction in body weight. The applicant is

Amylin.

- (10) US marketing exclusivity for the BYETTA formulations of synthetic exenatide for use in patients with type II diabetes mellitus who are using a thiazolidinedione alone or in combination with metformin but have not achieved adequate glycemic control, expired on 22 December 2009.
- (11) US marketing exclusivity for synthetic exenatide as a new chemical entity expired on 28 April 2010.
- (12) Country Comments: US application US2009215694 claims a lyophilized formulation comprising specified amounts of exenatide (exendin-4) and mannitol.
- (13) The term of US application US2009215694 has been disclaimed against numerous patents and ultimately from the normal expiry date of US patent US6902744.
- (14) Country Comments: Singapore patent SG81736 is based on WO0041548 and claims a method of lowering plasma glucagon in a subject, comprising administering a therapeutically effective glucagon lowering amount of a compound selected from an exendin, an exendin agonist, a modified exendin and a modified exendin agonist where the compounds have an amino acid sequence that is at least 31 amino acid residues in length.
- (15) Country Comments: Singapore patent SG81737 is based on WO0041546 and claims a formulation suitable for multi-use administration comprising an exendin agonist analogue, a buffer, an iso-osmolality modifier and about 0.005% to 1.0% (w/v) of a preservative selected from m-cresol, phenol, alcohol, methyl-, ethyl-, propyl- and butyl-paraben, where the formulation has a pH of between 3.0 and 6.0.
- (16) Country Comments: EP1658856 B is a divisional of EP1143989 B and claims the use of an exendin, an exendin agonist, a modified exendin or a modified exendin agonist in the manufacture of a formulation for use in therapeutic lowering of plasma glucagon. The formulation is used in treating necrolytic migratory erythema or glucagonoma.
- (17) EP1658856 B lapsed in Sweden in March 2010.
- (18) EP1658856 B lapsed in Portugal in July 2010.
- (19) EP1658856 B lapsed in the Netherlands in March 2010.

---

**In North America**

CAS  
STN North America  
P.O. Box 3012  
Columbus, Ohio 43210-0012 U.S.A.

CAS Customer Center:  
Phone: 800-753-4227 (North America)  
614-447-3700 (worldwide)  
Fax: 614-447-3751  
E-mail: [help@cas.org](mailto:help@cas.org)  
Internet: [www.cas.org](http://www.cas.org)

**In Europe**

FIZ Karlsruhe  
STN Europe  
P.O. Box 2465  
76012 Karlsruhe  
Germany  
Phone: +49-7247-808-555  
Fax: +49-7247-808-259  
E-mail: [helpdesk@fiz-karlsruhe.de](mailto:helpdesk@fiz-karlsruhe.de)  
Internet: [www.stn-international.com](http://www.stn-international.com)

**In Japan**

JAICI (Japan Association for  
International Chemical Information)  
STN Japan  
Nakai Building  
6-25-4 Honkomagome, Bunkyo-ku  
Tokyo 113-0021, Japan  
Phone: +81-3-5978-3601 (Technical Service)  
+81-3-5978-3621 (Customer Service)  
Fax: +81-3-5978-3600  
E-mail: [support@jaici.or.jp](mailto:support@jaici.or.jp) (Technical Service)  
[customer@jaici.or.jp](mailto:customer@jaici.or.jp) (Customer Service)  
Internet: [www.jaici.or.jp](http://www.jaici.or.jp)